Trial Profile
Double blind, multinational, multicentre, parallel-group design clinical trial of the efficacy and tolerability of CHF 1535 (beclomethasone dipropionate 100 microg + formoterol 6 microg) pMDI [pressurised Metered Dose Inhaler] via HFA-134a vs. fluticasone 125 microg + salmeterol 25 microg pMDI (Seretide) in the 12-week treatment of adult patients with moderate to severe persistent asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol (Primary) ; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ICAT-SE
- 01 Oct 2007 Study acronym identified
- 01 Oct 2007 Results have been published, including primary endpoint
- 25 Nov 2006 New trial record.